NRX Pharmaceuticals Book Value Per Share Growth & History (NRXP)
NRX Pharmaceuticals's book value per share was -$0.50 for fiscal 2025.
View full NRX Pharmaceuticals company overviewNRX Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.50 | $1.09 | — |
| 2024 | 2024-12-31 | -$1.59 | -$0.19 | — |
| 2023 | 2023-12-31 | -$1.40 | -$1.51 | — |
| 2022 | 2022-12-31 | $0.11 | -$3.43 | −96.85% |
| 2021 | 2021-12-31 | $3.54 | $13.72 | — |
| 2020 | 2020-12-31 | -$10.19 | -$9.12 | — |
| 2019 | 2019-12-31 | -$1.06 | -$2.21 | — |
| 2018 | 2018-12-31 | $1.15 | -$0.06 | −4.92% |
| 2017 | 2017-12-31 | $1.21 | — | — |
NRX Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.00 | $1.82 | — |
| Q1 2026 | 2026-03-31 | -$0.41 | $1.06 | — |
| Q4 2025 | 2025-12-31 | -$0.50 | $1.09 | — |
| Q3 2025 | 2025-09-30 | -$0.93 | $0.72 | — |
| Q2 2025 | 2025-06-30 | -$1.83 | -$0.12 | — |
| Q1 2025 | 2025-03-31 | -$1.47 | — | — |
| Q4 2024 | 2024-12-31 | -$1.59 | -$0.19 | — |
| Q3 2024 | 2024-09-30 | -$1.65 | -$0.91 | — |
| Q2 2024 | 2024-06-30 | -$1.70 | -$1.35 | — |
| Q4 2023 | 2023-12-31 | -$1.40 | -$1.51 | — |
| Q3 2023 | 2023-09-30 | -$0.74 | -$3.22 | — |
| Q2 2023 | 2023-06-30 | -$0.35 | -$4.15 | — |
| Q1 2023 | 2023-03-31 | -$0.04 | -$4.80 | — |
| Q4 2022 | 2022-12-31 | $0.11 | -$3.43 | −96.85% |
| Q3 2022 | 2022-09-30 | $2.48 | $1.04 | +72.02% |
| Q2 2022 | 2022-06-30 | $3.80 | $11.99 | — |
| Q1 2022 | 2022-03-31 | $4.76 | $3.27 | +220.03% |
| Q4 2021 | 2021-12-31 | $3.54 | $13.72 | — |
| Q3 2021 | 2021-09-30 | $1.44 | $2.10 | — |
| Q2 2021 | 2021-06-30 | -$8.18 | -$6.82 | — |
| Q1 2021 | 2021-03-31 | $1.49 | $2.89 | — |
| Q4 2020 | 2020-12-31 | -$10.19 | -$9.12 | — |
| Q3 2020 | 2020-09-30 | -$0.66 | -$1.77 | — |
| Q2 2020 | 2020-06-30 | -$1.36 | -$2.48 | — |
| Q1 2020 | 2020-03-31 | -$1.41 | -$2.53 | — |
| Q4 2019 | 2019-12-31 | -$1.06 | -$2.21 | — |
| Q3 2019 | 2019-09-30 | $1.11 | -$0.07 | −6.13% |
| Q2 2019 | 2019-06-30 | $1.12 | -$0.08 | −6.38% |
| Q1 2019 | 2019-03-31 | $1.12 | -$0.08 | −6.75% |
| Q4 2018 | 2018-12-31 | $1.15 | -$0.06 | −4.92% |
| Q3 2018 | 2018-09-30 | $1.18 | — | — |
| Q2 2018 | 2018-06-30 | $1.19 | — | — |
| Q1 2018 | 2018-03-31 | $1.20 | — | — |
| Q4 2017 | 2017-12-31 | $1.21 | — | — |
NRX Pharmaceuticals book value per share trends
Over the last five fiscal years, NRX Pharmaceuticals's book value per share increased from -$10.19 to -$0.50, a change of $9.68. The latest reported quarter, Q2 2026, shows -$0.00.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NRX Pharmaceuticals source filings ↗